We are the world’s largest publicly-funded international collaboration focused on the development of vaccines to prevent HIV/AIDS. Learn more >
Our sites conduct all phases of clinical trials - from evaluating experimental vaccines for safety and immunogenicity to testing vaccine efficacy. Learn more >
Worldwide, thousands of people have participated in HIV vaccine trials. Volunteers are the heroes of vaccine development. Learn more >
The Mbeya region in Tanzania is a remote, rural area that encompasses two major highways and is adjacent to two international borders. In the late 1980s, the HIV epidemic rapidly expanded in the Mbeya region, fueled by these unique geographic features and exacerbated by a lack of trained health staff, shortage of medicine, and a poor healthcare infrastructure. Read More.
Antibodies that are able to adhere to the outer shell of HIV can inactivate the virus, and potentially stop infection before it starts. However, HIV is one of the most changeable viruses discovered to date, and the strains in circulation vary widely. An ideal vaccine against HIV would produce antibodies that could inactivate all HIV strains, but the reality is that antibodies against one strain usually don’t work against others. Read more >
We support the next generation of HIV researchers with structured mentoring, projects, training, and networking opportunities. Learn more >
Getting the right test will prevent an incorrect diagnosis of HIV. Your study site or VISP Testing Service can provide the right test. Visit our frequently asked questions for more information.